COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

AVODART® Alopecia Post-marketing Surveillance (PMS) (AVODART®PMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01004809
Recruitment Status : Completed
First Posted : October 30, 2009
Last Update Posted : June 19, 2018
Information provided by (Responsible Party):

Brief Summary:
Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients

Condition or disease Intervention/treatment
Alopecia Drug: Dutasteride

Detailed Description:
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and effectiveness of dutasteride administered in Korean androgenetic alopecia patients according to the prescribing information

Layout table for study information
Study Type : Observational
Actual Enrollment : 712 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and Effectiveness of AVODART® Administered in Korean Androgenetic Alopecia Patients According to the Prescribing Information
Study Start Date : April 29, 2010
Actual Primary Completion Date : December 1, 2012
Actual Study Completion Date : December 21, 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Dutasteride

Group/Cohort Intervention/treatment
Patients administrated dutasteride with male hair loss
Drug: Dutasteride
Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Primary Outcome Measures :
  1. Occurrence of adverse event after dutasteride administration [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Occurrence of unexpected adverse drug reaction after dutasteride administration [ Time Frame: 2 years ]
  2. Occurrence of serious adverse events after dutasteride administration [ Time Frame: 2 years ]
  3. Effectiveness of dutasteride judged by a physician [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 41 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients administrated dutasteride with male pattern hair loss (androgenetic alopecia)

Inclusion Criteria:

  • Men (18-41 years of age) with male pattern hair loss (androgenetic alopecia)
  • Subjects with no experience of treatment using dutasteride
  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol
  • Subjects who prescribed with dutasteride according to the Prescribing Information

Exclusion Criteria:

  • Considering the nature of observational study, GSK Korea encourages the doctors participating in this study to enrol the subjects prescribed with dutasteride following the locally approved Prescribing Information. Subject who give informed consent is enrolled. However, if institution waives the requirement for informed consent, informed consent is not required. In this case, monitoring does not proceed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01004809

Layout table for location information
Korea, Republic of
GSK Investigational Site
Daejeon, Korea, Republic of, 301-721
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT01004809    
Other Study ID Numbers: 113797
First Posted: October 30, 2009    Key Record Dates
Last Update Posted: June 19, 2018
Last Verified: June 2018
Keywords provided by GlaxoSmithKline:
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
5-alpha Reductase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs